Thermo Fisher (TMO) EV/EBITDA Multiple

Graphic logo of Thermo Fisher Corp (TMO)

The strategic goal of Thermo Fisher Scientific (TMO) is to maintain its status as a defensive asset resilient to macro shocks. The business valuation via EV/EBITDA trends illustrates progress toward this goal, with the metric currently at 24.20. Growth is driven by a sales model based on consumables for high-end equipment and impeccable liquidity, creating insurmountable barriers for competitors in the medical diagnostics sector.

TMO (Thermo Fisher Corp) Business Value to Operating Income Before Depreciation history from 11/23/2025 to 11/15/2026

TMO (Thermo Fisher): analytical breakdowns and indicator data

- current price and projected stock value:
Fundamental company valuation:thermofisher.com TMO
Product sample of thermofisher.com

This metric compares the total enterprise value, including debt and taxes, with its operating profit before depreciation and amortization. This ratio reveals the actual value of the company by neutralizing distortions caused by excessive leverage. For Thermo Fisher Scientific (TMO), this is critical, as the outsourcing of logistics and services impacts the cost structure and debt load. Analyzing the EV/EBITDA multiple, accounting for net debt, allows for the timely identification of capital impairment risks.

Analysis of competing companies

EV/EBITDA Multiple ABT (abbott.com)|Enterprise Value to Operating Income Before Depreciation Ratio GEHC (GE HealthCare)|Mettler-Toledo - EV/EBITDA Multiple|Waters Corp. (WAT) - Enterprise Value to EBITDA Ratio|TECH: EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio Bruker Corporation|Enterprise Value to EBITDA Ratio AZTA|VREX: Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Semler Scientific Inc (SMLR)|Enterprise Value to EBITDA Ratio Butterfly Network BFLY|EV/EBITDA Multiple MLAB (mesalabs.com)|QSI: Enterprise Value to Operating Income Before Depreciation|Nano-X - EV/EBITDA Multiple|QTRX (Quanterix Corporation) - Enterprise Value to Operating Income Before Depreciation|MASS: EV/EBITDA Multiple|CapsoVision Medical (CV) - EV/EBITDA Multiple|MXCT (MaxCyte Inc) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio Rapid Micro Biosystems (RPID)|EV/EBITDA Multiple SEER|EV/EBITDA Multiple hyperfine.io (HYPR)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization FONAR FONR|Business Value to Operating Income Before Depreciation DXR|MDAI: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation VIVS (Organovo Holdings, Inc.)|ACON: EV/EBITDA Multiple|Company Value to EBITDA Akoya (AKYA)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization thermogenesis.com|TLIS - Enterprise Value to EBITDA Multiple|Enterprise Value to EBITDA Ratio TTOO (T2 Biosystems Inc.)